GlassScriptPhysician profile
Amy Youman
NPI 1811495153
$10,725.37
in general payments reported to CMS, 2019-2025
64 companies · $3,546 in 2025
The $3,546 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $1,176 · 2023: $2,442 · 2024: $3,316 · 2025: $3,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,693 · Education: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,693.12 |
| Education | $610.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $811.97 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Novartis Pharmaceuticals Corporation | $710.20 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $661.56 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $579.01 | 2023-2025 | Vyloy, Xospata, Padcev |
| Incyte Corporation | $557.22 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $473.17 | 2021-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $470.53 | 2022-2025 | |
| Janssen Biotech, INC. | $445.46 | 2022-2025 | Erleada, Rybrevant, Balversa |
| Astrazeneca Pharmaceuticals LP | $349.68 | 2022-2025 | Enhertu, Calquence |
| Genentech USA, INC. | $328.97 | 2022-2025 | Venclexta, Tecentriq, Polivy |
| Celgene Corporation | $302.10 | 2022-2025 | Reblozyl, Pomalyst |
| Stemline Therapeutics INC. | $300.59 | 2023-2025 | Orserdu |
| Eisai INC. | $297.88 | 2022-2025 | |
| Gilead Sciences, INC. | $297.49 | 2022-2025 | Trodelvy |
| Sobi, INC | $241.16 | 2022-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $232.13 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $230.07 | 2022-2025 | Libtayo, Lynozyfic |
| Exelixis INC. | $211.44 | 2023-2025 | Cabometyx |
| Genzyme Corporation | $203.35 | 2022-2025 | |
| Seagen INC. | $200.68 | 2022-2023 | Tukysa, Adcetris, Tivdak |
| Lilly USA, LLC | $191.42 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Tersera Therapeutics LLC | $185.76 | 2023-2025 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $183.34 | 2022-2025 | Fruzaqla, Ninlaro, Iclusig |
| Array Biopharma INC | $145.63 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $137.88 | 2022-2025 | Onivyde, Somatuline Depot |
| Taiho Oncology, INC. | $132.83 | 2022-2025 | |
| Glaxosmithkline, LLC. | $118.58 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Puma Biotechnology, INC. | $116.61 | 2022-2024 | Nerlynx |
| Beone Medicines USA, INC. | $109.56 | 2025 | Brukinsa, Tevimbra |
| Dendreon Pharmaceuticals LLC | $98.77 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $96.29 | 2022-2024 | Cosela |
| Emd Serono, INC. | $87.31 | 2024-2025 | |
| Mirati Therapeutics, INC. | $81.77 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $75.29 | 2024-2025 | |
| Foundation Medicine, INC. | $70.41 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.18 | 2024-2025 | |
| Legend Biotech USA INC. | $62.16 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $59.64 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $54.91 | 2023-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $53.65 | 2022-2024 | Besremi |
| G1 Therapeutics, INC. | $52.02 | 2022-2023 | Cosela |
| Recordati_rare_diseases_inc. | $51.55 | 2023-2025 | Sylvant, Enjaymo |
| Beigene USA, INC. | $45.75 | 2023-2024 | Brukinsa |
| Geron Corporation | $45.22 | 2025 | Rytelo |
| Kite Pharma, INC. | $42.87 | 2023-2024 | Yescarta |
| Cti Biopharma Corp. | $42.79 | 2022-2023 | Vonjo |
| Csl Behring | $39.05 | 2023-2024 | Afstyla, Idelvion |
| Amgen INC. | $34.51 | 2023 | Lumakras |
| Genmab U.S., INC. | $29.59 | 2025 | Epkinly |
| Alnylam Pharmaceuticals INC. | $27.41 | 2024 | Givlaari |
| Blueprint Medicines Corporation | $24.33 | 2024 | Ayvakit |
| Iovance Biotherapeutics, INC. | $23.36 | 2025 | Amtagvi |
| Abbvie INC. | $23.30 | 2024 | |
| Azurity Pharmaceuticals, INC. | $23.02 | 2025 | Danziten |
| Nuvation Bio INC. | $22.61 | 2025 | Ibtrozi |
| Adaptive Biotechnologies Corporation | $22.48 | 2023 | Clonoseq |
| Agios Pharmaceuticals, INC. | $21.83 | 2025 | Pyrukynd |
| Tolmar, INC. | $20.64 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $20.64 | 2025 | Rubraca |
| Coherus Oncology, INC. | $16.51 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.89 | 2024 | Xarelto |
| Syndax Pharmaceuticals, INC. | $15.85 | 2025 | |
| Karyopharm Therapeutics INC. | $14.15 | 2025 | Xpovio |
| Kyowa Kirin, INC. | $13.35 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Youman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.